Teva’s patent, disparagement strategies for MS drug attract EU antitrust fine
MLex Summary: The European Commission has imposed a sanction of 462.6 million euros on Teva Pharmaceutical for abusing the patent system to protect its blockbuster multiple sclerosis drug Copaxone. It was...To view the full article, register now.
Already a subscriber? Click here to view full article